Kiadis Pharma N.V. Company Profile

15:06 EDT 26th March 2019 | BioPortfolio

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT), being graft-versus-host disease (GVHD), cancer relapse, opportunistic infections and limited matched donor availability. HSCT is generally regarded as the most effective curative approach to blood cancers and certain inherited blood disorders and the Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.

News Articles [699 Associated News Articles listed on BioPortfolio]

Kiadis Pharma (KDS) - Termination of coverage

Edison Investment Research - Pharmaceuticals & healthcare - Kiadis Pharma: Edison Investment Research is terminating coverage on Kiadis Pharma (KDS). Please note you should no longer rely on any previ...

Kiadis Pharma appoints senior positions in Boston

Biopharmaceutical company, Kiadis Pharma, has appointed two new key personnel in the US

Kiadis Pharma names former Ablynx exec as chief scientific officer

Robert Friesen, former chief scientific officer at Ablynx, will assume the same role at Kiadis Pharma, an immunotherapy compa -More- 

Kiadis closes €31.2mm PIPE

Kiadis Pharma NV (developing cell-based immunotherapies for cancer) raised €31.2mm ($35.8mm) through an oversubscribed private placement to institutional investors of 3.9mm new shares at €8 (a 38%...

Company focus: Kiadis

Amsterdam-based Kiadis has a unique approach to tackling the ‘terrifying’ graft versus host disease that can result from bone marrow transplants. We spoke to CEO Arthur Lahr to find out wh...

Former Ablynx exec joins Kiadis as Chief Scientific Officer

Former Ablynx exec joins Kiadis as Chief Scientific Officer  #pharma

Kiadis Pharma to present at Biotech Showcase 2019

    Kiadis Pharma to present at Biotech Showcase 2019 Amsterdam, The Netherlands, January 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Eurone...

Kiadis Pharma to present at upcoming investor conferences in March 2019

                                                   Kiadis Pharma to present at upcoming investor conferences in March 2019 Amsterda...

Drugs and Medications [53 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 1 mg

Urea [mayne pharma inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [aventis pharma ltd.]


Ribavirin [aurobindo pharma limited]


PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Establishing and Maintaining a Robust Sample Management System.

This paper has been written by the SLAS Sample Management Special Interest Group to serve as a guide to the best practices and methods in establishing and maintaining a high-quality sample management ...

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [801 Associated Companies listed on BioPortfolio]

Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical company developing products that offer novel treatment options for terminally ill cancer patients addressing significant unmet medical needs. Th...

Kiadis B.V

“Kiadis : Your partner for discovery of novel high value compounds”. Kiadis is a drug disKiadis Pharma is an oncology company focused specifically on complications and limitations of bone marrow t...

Kiadis Pharma N.V.

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell-based immunotherapy products for the treatment of...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

More Information about "Kiadis Pharma N.V." on BioPortfolio

We have published hundreds of Kiadis Pharma N.V. news stories on BioPortfolio along with dozens of Kiadis Pharma N.V. Clinical Trials and PubMed Articles about Kiadis Pharma N.V. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kiadis Pharma N.V. Companies in our database. You can also find out about relevant Kiadis Pharma N.V. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Corporate Database Quicklinks

Searches Linking to this Company Record